Biotechnology company IN8bio, develops allogeneic drugs for cancer treatment based on gamma-delta T cells, located in 1 research phase, attracted 40 million dollars, releasing 4 million shares in 10 dollars - the minimum price of the stated range from 10 to 12 Dollars. Taking into account the actual IPO price, the total diluted market value of the company was 195 million dollars.
The company's product line includes INB-200 candidate products, which is currently in 1 research phase for the treatment of newly diagnosed glioblastoma, и INB-100, located in 1 phase of research in patients with leukemia, undergoing hematopoietic stem cell transplantation. The company plans to apply for research authorization for its three drug candidates in 1 Half 2022 And 2023 years.
IN8bio plans listing on the stock exchange Nasdaq under the ticker INAB. The only organizer of the issue of shares was B. Riley Securities.
